Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Dugan

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
The Journal of Experimental Medicine|August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancerApostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
The Journal of Experimental Medicine|August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancerApostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Pageof 2